Results 211 to 220 of about 6,546 (245)

Long-Term Dynamics of CSF and Serum Neurofilament Light Chain in Adult Patients With 5q Spinal Muscular Atrophy Treated With Nusinersen. [PDF]

Neurology
Cordts I, Fuetterer C, Wachinger A, von Heynitz R, Kessler T, Freigang M, Quinten AL, Bjelica B, Brakemeier S, Hobbiebrunken E, Hagenacker T, Petri S, Koch JC, Hahn A, Lingor P, Deschauer M, Günther R, Weiler M, Haller B, Feneberg E.   +19 more
europepmc   +1 more source

The Effect of Aerobic Exercise Training on Patients with Type III Spinal Muscular Atrophy. [PDF]

J Clin Med
Mergen Kilic S, Mutluay F, Cakar A, Giris M, Durmus H, Bingul I, Gedikbasi A, Kucukgergin C, Uyguner ZO, Parman Y.   +9 more
europepmc   +1 more source

Nusinersen for children with type I spinal muscular atrophy: 4 years' clinical experience in Turkish cohort. [PDF]

Front Neurol
Bektaş Ö, Gülşen M, Dursun OB, Tekin A, Yüksel D, Demir E, Öztürk G, Saltık S, Hergüler Ö, Özçelik AA, Tan H, Özgör B, Ekici A, Yüksel MF, Şahin S, Duman Ö, Kömür M, Baydan F, Yıldız EP, Kara B, Yiş U, Kanmaz S, Çarman KB, Arslan EA, Canpolat M, Güven AS, Öztuncer G, Ünalp A, Ardıçlı D, Karaduman AA, Zararsız G, Deda G, Turkish SMA Study Group.   +32 more
europepmc   +1 more source

Six‐minute walk test as outcome measure of fatigability in adults with spinal muscular atrophy treated with nusinersen

Alessandra Govoni, Giulia Ricci, Silvia Bonanno, Luca Bello, Francesca Magri, Megi Meneri, Francesca Torri, Claudia Caponnetto, Luigia Passamano, Marina Grandis, Francesca Trojsi, Federica Cerri, G Gadaleta, Giuliana Capece, Luca Caumo, Raffaella Tanel, Elena Saccani, Veria Vacchiano, Gianni Sorarù, Eustachio D’Errico, Irene Tramacere, Sara Bortolani, Enrica Rolle, Cinzia Gellera, Riccardo Zanin, Mauro Silvestrini, Luisa Politano, Angelo Schenone, Stefano C. Previtali, Angela Berardinelli, Mara Turri, Lorenzo Verriello, Michela Coccia, Renato Mantegazza, Rocco Liguori, Massimiliano Filosto, Maria Antonietta Maioli, Isabella Laura Simone, Tiziana Mongini, Stefania Corti, Maria Laura Manca, Elena Pegoraro, Gabriele Siciliano, Giacomo P. Comi, Lorenzo Maggi   +44 more
openalex   +1 more source

Healthcare Resource Utilization, Economic Burden, and Multi-Level Medical Security System for Individuals with Spinal Muscular Atrophy in Shaanxi Province, China. [PDF]

Healthcare (Basel)
Zhao M, Ding S, Zhao Y, Lin C, Han Y.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Laboratory monitoring of nusinersen safety

Muscle & Nerve, 2021
AbstractIntroductionThis retrospective study reports our tertiary care center's experience with intrathecal nusinersen administration in children and adults with spinal muscular atrophy (SMA).MethodsWe reviewed safety monitoring laboratory results and need for procedural sedation and fluoroscopy‐guidance in all SMA patients receiving nusinersen between
Natalie L. Goedeker, Craig M. Zaidman, Jennifer L Gibbons, Anne M. Connolly, Arun S. Varadhachary   +4 more
openaire   +3 more sources

Nusinersen (Spinraza)

Canadian Journal of Health Technologies, 2022
CADTH recommends that Spinraza should not be reimbursed by public drug plans for the treatment of patients with type II and type III 5q spinal muscular atrophy (SMA) regardless of ambulatory status if initiated in patients older than 18 years of age. No randomized clinical trials evaluating the efficacy or safety of Spinraza in treatment ...
openaire   +1 more source

Nusinersen for adults with spinal muscular atrophy

Neurological Sciences, 2023
Nusinersen was effective in improving motor function and survival in infantile and childhood-onset spinal muscular atrophy (SMA), and the value of real-world experiences in adult SMA patients increase gradually. Here, we present our clinical experience in adult SMA patients treated with nusinersen according to CHERISH study.Thirty-two SMA patients ...
Doruk Arslan, Berin Inan, Muhammed Kilinc, Can Ebru Bekircan-Kurt, Sevim Erdem-Ozdamar, Ersin Tan   +5 more
openaire   +2 more sources